MediWound Ltd. (MDWD)
Chart Events
Performance Outlook
| Previous Close | 14.12 |
| Open | 14.00 |
| Bid | 12.00 x 1100 |
| Ask | 14.21 x 1300 |
| Day's Range | 13.50 - 14.55 |
| 52 Week Range | 8.05 - 17.25 |
| Volume | |
| Avg. Volume | 61,733 |
| Market Cap | 81.529M |
| Beta (5Y Monthly) | 1.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.52 |
| Earnings Date | Mar 15, 2023 - Mar 20, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.17 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MDWD
Related Research
- MediWound Ltd.Daily – Vickers Top Insider Picks for 12/30/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.RatingFair ValueEconomic Moatlast monthArgus Research
- TipRanks
Buy These 2 Stocks Before They Jump Over 80%, Say Analysts
The latest Consumer Price Index (CPI) figures showed that inflation is still easing, having dropped for the 6th consecutive month. The CPI for December rose by 6.5% from the same period a year ago and fell by 0.1% compared to November, thereby meeting Street expectations. There are still areas of concern, though, such as services inflation, which might put a spanner in the works for investors hoping the latest readout will cause the Fed to put the brakes on its rate-hiking endeavors. Additionall
- Simply Wall St.
MediWound (NASDAQ:MDWD) investors are sitting on a loss of 61% if they invested five years ago
This month, we saw the MediWound Ltd. ( NASDAQ:MDWD ) up an impressive 39%. But that is little comfort to those holding...
- Benzinga
FDA Approves MediWound's NexoBrid For Burn Treatment
The FDA has approved MediWound Ltd's (NASDAQ: MDWD) NexoBrid (anacaulase-bcdb) to remove eschar in adults with deep partial-thickness and/or full-thickness thermal burns. NexoBrid, a botanical drug product containing proteolytic enzymes, is already approved in 43 countries. Recently, MediWound signed an agreement with Triskel Integrated Services to market and distribute NexoBrid in Switzerland, with a launch planned for Q1 of 2023. Triskel also holds the distribution rights of NexoBrid in France
